Should clarify, maybe not a "priority" over Cantrixl per say,...

Should clarify, maybe not a "priority" over Cantrixl per say, but a smoother sailing i guess, for Anisina, within it's own.

They're both a go. Drugs are chosen, FDA meetings, manufacturing, clinical protocols, etc..

Still will bet, the non-cancer cell line Cantrixl effected, will be an opportunity to cure an additional issue, like Ninja eluded to. Besides, they're writing the protocol, so they definitely do not sound concerned, like it was vaguely stated. Could be setting up for an additional surprise.

Glta!
Chris